Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333484 | 0.92 | USP14 (0.45) | TP53SMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL334103 | 0.90 | PTGES (0.50) | TP53SMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL333467 | 0.89 | SMN1; SMN2 (0.44) | TP53SMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL334059 | 0.89 | ALOX5 (0.45) | TP53SMN1; SMN2THRBPTGESMEN1 | |
| SCHEMBL334124 | 0.87 | ALOX5 (0.43) | TP53SMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL333541 | 0.85 | PPARG (0.47) | TP53SMN1; SMN2THRBPTGESMAPT | |
| SCHEMBL333920 | 0.84 | KMT2A (0.57) | SMN1; SMN2PTGESMEN1KMT2AMAPT | |
| SCHEMBL333461 | 0.82 | THRB (0.43) | TP53SMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL334287 | 0.82 | FFAR1 (0.43) | TP53SMN1; SMN2THRBMEN1KMT2A | |
| SCHEMBL333533 | 0.82 | TP53 (0.54) | TP53SMN1; SMN2THRBPOLBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | TP53 738/4885SMN1; SMN2 3963/4885THRB 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.